Home › Compare › PRTK vs HDV

PRTK vs HDV: Dividend Comparison 2026

PRTK yields 1433.77% · HDV yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRTK wins by $465580976.90M in total portfolio value
10 years
PRTK
PRTK
● Live price
1433.77%
Share price
$2.23
Annual div
$31.97
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$465580976.93M
Annual income
$409,409,349,290,672.40
Full PRTK calculator →
HDV
iShares Core High Dividend ETF
● Live price
2.92%
Share price
$135.39
Annual div
$3.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$352.73
Full HDV calculator →

Portfolio growth — PRTK vs HDV

📍 PRTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRTKHDV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRTK + HDV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PRTK pays
HDV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRTK
Annual income on $10K today (after 15% tax)
$121,870.18/yr
After 10yr DRIP, annual income (after tax)
$347,997,946,897,071.50/yr
HDV
Annual income on $10K today (after 15% tax)
$248.52/yr
After 10yr DRIP, annual income (after tax)
$299.82/yr
At 15% tax rate, PRTK beats the other by $347,997,946,896,771.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRTK + HDV for your $10,000?

PRTK: 50%HDV: 50%
100% HDV50/50100% PRTK
Portfolio after 10yr
$232790488.48M
Annual income
$204,704,674,645,512.56/yr
Blended yield
87.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PRTK right now

PRTK
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Altman Z
-9.7
Piotroski
4/9
HDV
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRTK buys
0
HDV buys
0
No recent congressional trades found for PRTK or HDV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRTKHDV
Forward yield1433.77% ✓2.92%
Annual dividend / share$31.97 ✓$3.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$465580976.93M ✓$24.3K
Annual income after 10y$409,409,349,290,672.40 ✓$352.73
Total dividends collected$461472805.42M ✓$3.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PRTK vs HDV ($10,000, DRIP)

YearPRTK PortfolioPRTK Income/yrHDV PortfolioHDV Income/yrGap
1← crossover$154,077$143,376.68$11,002$292.38+$143.1K → PRTK
2$2,229,442$2,064,579.75$12,084$300.36+$2.22M → PRTK
3$30,304,969$27,919,466.07$13,250$308.02+$30.29M → PRTK
4$387,109,855$354,683,538.63$14,506$315.35+$387.10M → PRTK
5$4,648,468,715$4,234,261,169.66$15,858$322.35+$4648.45M → PRTK
6$52,493,108,361$47,519,246,835.85$17,313$329.04+$52493.09M → PRTK
7$557,675,953,215$501,508,327,268.83$18,878$335.42+$557675.93M → PRTK
8$5,576,078,691,653$4,979,365,421,713.55$20,560$341.49+$5576078.67M → PRTK
9$52,496,848,258,695$46,530,444,058,626.19$22,367$347.25+$52496848.24M → PRTK
10$465,580,976,927,476$409,409,349,290,672.40$24,307$352.73+$465580976.90M → PRTK

PRTK vs HDV: Complete Analysis 2026

PRTK — Stock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Full PRTK Calculator →

HDV — ETF

The iShares Core High Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full HDV Calculator →
📬

Get this PRTK vs HDV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRTK vs SCHDPRTK vs JEPIPRTK vs OPRTK vs KOPRTK vs MAINPRTK vs VYMPRTK vs DVYPRTK vs SPHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.